19:58:31 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande



2025-02-20 Bokslutskommuniké 2024
2024-11-07 Kvartalsrapport 2024-Q3
2024-08-19 Kvartalsrapport 2024-Q2
2024-05-31 X-dag ordinarie utdelning PLUN 0.00 SEK
2024-05-30 Årsstämma 2024
2024-05-16 Kvartalsrapport 2024-Q1
2024-02-16 Bokslutskommuniké 2023
2023-11-07 Kvartalsrapport 2023-Q3
2023-10-12 Extra Bolagsstämma 2023
2023-07-14 Kvartalsrapport 2023-Q2
2023-05-17 Kvartalsrapport 2023-Q1
2023-05-05 X-dag ordinarie utdelning PLUN 0.00 SEK
2023-05-04 Årsstämma 2023
2023-02-15 Bokslutskommuniké 2022
2022-10-21 Kvartalsrapport 2022-Q3
2022-07-14 Kvartalsrapport 2022-Q2
2022-05-06 X-dag ordinarie utdelning PLUN 0.00 SEK
2022-05-05 Kvartalsrapport 2022-Q1
2022-05-05 Årsstämma 2022
2022-02-18 Bokslutskommuniké 2021
2021-10-22 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-12 X-dag ordinarie utdelning PLUN 0.00 SEK
2021-05-11 Årsstämma 2021
2021-05-07 Kvartalsrapport 2021-Q1
2021-02-19 Bokslutskommuniké 2020
2020-10-23 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-08 X-dag ordinarie utdelning PLUN 0.00 SEK
2020-05-07 Årsstämma 2020
2020-05-07 Kvartalsrapport 2020-Q1
2020-02-13 Bokslutskommuniké 2019
2019-10-24 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-05-17 Årsstämma 2019
2019-05-08 X-dag ordinarie utdelning PLUN 0.00 SEK
2019-04-16 Årsstämma 2019
2019-04-16 Kvartalsrapport 2019-Q1
2019-02-22 Bokslutskommuniké 2018
2018-11-14 Kvartalsrapport 2018-Q3
2018-08-21 Kvartalsrapport 2018-Q2
2018-05-17 X-dag ordinarie utdelning PLUN 0.00 SEK
2018-05-16 Kvartalsrapport 2018-Q1
2018-05-16 Årsstämma 2018
2018-02-28 Bokslutskommuniké 2017
2017-11-16 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-05-10 X-dag ordinarie utdelning PLUN 0.00 SEK
2017-05-09 Årsstämma 2017
2017-05-09 Kvartalsrapport 2017-Q1
2017-02-23 Bokslutskommuniké 2016
2016-11-10 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-05-18 X-dag ordinarie utdelning PLUN 0.00 SEK
2016-05-17 Kvartalsrapport 2016-Q1
2016-05-17 Årsstämma 2016
2016-02-26 Bokslutskommuniké 2015
2015-11-13 Kvartalsrapport 2015-Q3
2015-08-28 Kvartalsrapport 2015-Q2
2015-05-12 X-dag ordinarie utdelning PLUN 0.00 SEK
2015-05-11 Kvartalsrapport 2015-Q1
2015-05-11 Årsstämma 2015
2015-02-27 Bokslutskommuniké 2014
2014-11-28 Kvartalsrapport 2014-Q3
2014-08-29 Kvartalsrapport 2014-Q2
2014-05-14 Kvartalsrapport 2014-Q1
2014-05-06 X-dag ordinarie utdelning PLUN 0.00 SEK
2014-05-05 Årsstämma 2014
2014-02-22 Bokslutskommuniké 2013
2013-11-20 Kvartalsrapport 2013-Q3


ListaFirst North Stockholm
ProstaLund är verksamt inom medicinteknik. Bolaget är specialiserat inom forskning, utveckling och vidare behandling av prostataförstoring (BPH). Via bolagets CoreTherm ges värmebehandling av godartad prostataförstoring, utan behov av ett kirurgiskt ingrepp. Visionen är att erbjuda alternativa lösningar gentemot traditionella tillvägagångssätt. Bolaget grundades ursprungligen under 1991 och har verksamhet på global nivå, med huvudkontoret i Lund.
2024-02-27 14:00:00

In a newly published study [1] in The Canadian Journal of UrologyTM, Transurethral Intraprostatic Anesthesia with Schelin Catheter®, effectively controlled operative and postoperative pain related to water vapor therapy.

The standard analgesic approach for water vapor therapy is transrectal periprostatic block (PNB) or systemic sedation anesthesia. PNB is uncomfortable and holds a risk of infection. Sedation poses safety risks and presence of an anesthesiology team.

Use of transurethral intraprostatic anesthesia (TUIA) using Schelin Catheter® provides a non-invasive, efficient technique for out-patient, office-based procedures.

In the article “Use of the Schelin Catheter® for transurethral intraprostatic anesthesia prior to Rezūm treatment” the research team, with urologists from Canada, Italy, and USA, evaluated the efficacy of TUIA via Schelin Catheter® on ten consecutive patients, by monitoring pain before, during and after the water vapor therapy.

The authors reported that Schelin Catheter® was simple to prepare and manipulate, and that the administration of anesthetics resulted in effective pain control. Their experience when using Schelin Catheter®, is that is more efficient compared to PNB, general anesthesia and intravenous sedation. “Given the reduced need for equipment, set-up, and training compared to other analgesic methods, time is greatly optimized by using the Schelin Catheter®.”

Dr Kevin Zorn, former Associate Professor of Urology at University of Montreal Hospital Center and University of Chicago, current founder, and director of BPH Canada Prostate Surgery Institute “-While most urological procedures of the prostate require general anesthesia or transrectal PNB (along with their associated risks), these preoperative measures require expensive equipment and pose the risk of complications that can negatively affect patient outcomes and experience. Given our current results, TUIA via the novel Schelin Catheter®, is demonstrably an effective, efficient, non-invasive analgesic method that reduces cost and training, bridging the gap between preoperative care and emerging BPH office-based MISTs.”

“We are encouraged to see how efficient and easy to use our Schelin Catheter® is, and we look forward to continuing working with urologist across the globe in our mission to improve patient outcome” says Anders Kristensson, CEO of ProstaLund.

  1. https://canjurol.com/how-i-do-it
  2. MIST – Minimally Invasive Surgery Techniques